Fig. 9 | Nature Communications

Fig. 9

From: LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

Fig. 9

Schematic depiction of lncRNA-p21/EZH2/STAT3 pathway. Enz treatment induces lncRNA-p21 expression via regulating the AR binding to the lncRNA-p21 promoter in PCa cells. Highly expressed lncRNA-p21 competes with Hotair to interact with EZH2 and disrupt PRC2 complex (SUZ12 and EED). At the same time, lncRNA-p21 promotes AKT phosphorylated EZH2 on Serine 21 and enhances the STAT3 methylation by EZH2. The methylated STAT3 was activated and promotes the NED

Back to article page